ID   NOTC2_HUMAN             Reviewed;        2471 AA.
AC   Q04721; Q5T3X7; Q99734; Q9H240;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   03-APR-2007, sequence version 3.
DT   12-OCT-2022, entry version 242.
DE   RecName: Full=Neurogenic locus notch homolog protein 2 {ECO:0000305};
DE            Short=Notch 2;
DE            Short=hN2;
DE   Contains:
DE     RecName: Full=Notch 2 extracellular truncation;
DE              Short=N2ECD {ECO:0000303|PubMed:25985737};
DE   Contains:
DE     RecName: Full=Notch 2 intracellular domain;
DE              Short=N2ICD {ECO:0000303|PubMed:25985737};
DE   Flags: Precursor;
GN   Name=NOTCH2 {ECO:0000312|HGNC:HGNC:7882};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Blaumueller C.M., Mann R.S.;
RT   "Complete human notch 2 (hN2) cDNA sequence.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Mammary tumor;
RA   Correa R.G., Camargo A.A., Moreira E.S., Simpson A.J.G.;
RT   "Human Notch2, a novel member of cell-fate determining NOTCH family.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 967-1229.
RC   TISSUE=T-cell;
RA   Lemasson I., Devaux C., Mesnard J.-M.;
RT   "Partial sequence of EGF-like repeat domain of human Notch2 mRNA.";
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1810-2447.
RC   TISSUE=Brain;
RX   PubMed=1303260; DOI=10.1038/ng1092-119;
RA   Stifani S., Blaumueller C.M., Redhead N.J., Hill R.E.,
RA   Artavanis-Tsakonas S.;
RT   "Human homologs of a Drosophila enhancer of split gene product define a
RT   novel family of nuclear proteins.";
RL   Nat. Genet. 2:119-127(1992).
RN   [6]
RP   PROTEOLYTIC PROCESSING, AND SUBCELLULAR LOCATION.
RX   PubMed=9244302; DOI=10.1016/s0092-8674(00)80336-0;
RA   Blaumueller C.M., Qi H., Zagouras P., Artavanis-Tsakonas S.;
RT   "Intracellular cleavage of Notch leads to a heterodimeric receptor on the
RT   plasma membrane.";
RL   Cell 90:281-291(1997).
RN   [7]
RP   IDENTIFICATION OF LIGANDS.
RX   PubMed=10079256; DOI=10.1016/s0002-9440(10)65325-4;
RA   Gray G.E., Mann R.S., Mitsiadis E., Henrique D., Carcangiu M.-L., Banks A.,
RA   Leiman J., Ward D., Ish-Horowitz D., Artavanis-Tsakonas S.;
RT   "Human ligands of the Notch receptor.";
RL   Am. J. Pathol. 154:785-794(1999).
RN   [8]
RP   INTERACTION WITH MAML1.
RX   PubMed=11101851; DOI=10.1038/82644;
RA   Wu L., Aster J.C., Blacklow S.C., Lake R., Artavanis-Tsakonas S.,
RA   Griffin J.D.;
RT   "MAML1, a human homologue of Drosophila mastermind, is a transcriptional
RT   co-activator for NOTCH receptors.";
RL   Nat. Genet. 26:484-489(2000).
RN   [9]
RP   INTERACTION WITH MAML2 AND MAML3.
RX   PubMed=12370315; DOI=10.1128/mcb.22.21.7688-7700.2002;
RA   Wu L., Sun T., Kobayashi K., Gao P., Griffin J.D.;
RT   "Identification of a family of mastermind-like transcriptional coactivators
RT   for mammalian notch receptors.";
RL   Mol. Cell. Biol. 22:7688-7700(2002).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   INTERACTION WITH HIF1AN.
RX   PubMed=17573339; DOI=10.1074/jbc.m704102200;
RA   Coleman M.L., McDonough M.A., Hewitson K.S., Coles C., Mecinovic J.,
RA   Edelmann M., Cook K.M., Cockman M.E., Lancaster D.E., Kessler B.M.,
RA   Oldham N.J., Ratcliffe P.J., Schofield C.J.;
RT   "Asparaginyl hydroxylation of the Notch ankyrin repeat domain by factor
RT   inhibiting hypoxia-inducible factor.";
RL   J. Biol. Chem. 282:24027-24038(2007).
RN   [12]
RP   INTERACTION WITH MDK.
RX   PubMed=18469519; DOI=10.4161/cc.7.11.5952;
RA   Huang Y., Hoque M.O., Wu F., Trink B., Sidransky D., Ratovitski E.A.;
RT   "Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-
RT   Stat3 signaling in human keratinocytes.";
RL   Cell Cycle 7:1613-1622(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1716; THR-1802; SER-1804;
RP   THR-1808; SER-1845; SER-2070; SER-2081 AND THR-2097, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   HYDROXYLATION BY HIF1AN.
RX   PubMed=18299578; DOI=10.1073/pnas.0711591105;
RA   Zheng X., Linke S., Dias J.M., Zheng X., Gradin K., Wallis T.P.,
RA   Hamilton B.R., Gustafsson M., Ruas J.L., Wilkins S., Bilton R.L.,
RA   Brismar K., Whitelaw M.L., Pereira T., Gorman J.J., Ericson J., Peet D.J.,
RA   Lendahl U., Poellinger L.;
RT   "Interaction with factor inhibiting HIF-1 defines an additional mode of
RT   cross-coupling between the Notch and hypoxia signaling pathways.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:3368-3373(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778 AND SER-1845, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   INVOLVEMENT IN HJCYS, AND VARIANTS HJCYS 2208-GLN--ALA-2471 DEL;
RP   2223-GLN--ALA-2471 DEL AND 2360-GLN--ALA-2471 DEL.
RX   PubMed=21681853; DOI=10.1002/humu.21546;
RG   FORGE Canada Consortium;
RA   Majewski J., Schwartzentruber J.A., Caqueret A., Patry L., Marcadier J.,
RA   Fryns J.P., Boycott K.M., Ste-Marie L.G., McKiernan F.E., Marik I.,
RA   Van Esch H., Michaud J.L., Samuels M.E.;
RT   "Mutations in NOTCH2 in families with Hajdu-Cheney syndrome.";
RL   Hum. Mutat. 32:1114-1117(2011).
RN   [18]
RP   FUNCTION, INVOLVEMENT IN HJCYS, AND VARIANTS HJCYS 2285-GLN--ALA-2471 DEL;
RP   2317-GLN--ALA-2471 DEL AND 2373-TYR--ALA-2471 DEL.
RX   PubMed=21378989; DOI=10.1038/ng.778;
RA   Isidor B., Lindenbaum P., Pichon O., Bezieau S., Dina C., Jacquemont S.,
RA   Martin-Coignard D., Thauvin-Robinet C., Le Merrer M., Mandel J.L.,
RA   David A., Faivre L., Cormier-Daire V., Redon R., Le Caignec C.;
RT   "Truncating mutations in the last exon of NOTCH2 cause a rare skeletal
RT   disorder with osteoporosis.";
RL   Nat. Genet. 43:306-308(2011).
RN   [19]
RP   FUNCTION, INVOLVEMENT IN HJCYS, TISSUE SPECIFICITY, AND VARIANTS HJCYS
RP   2140-GLN--ALA-2471 DEL; 2208-GLN--ALA-2471 DEL; 2325-GLN--ALA-2471 DEL AND
RP   2400-ARG--ALA-2471 DEL.
RX   PubMed=21378985; DOI=10.1038/ng.779;
RA   Simpson M.A., Irving M.D., Asilmaz E., Gray M.J., Dafou D., Elmslie F.V.,
RA   Mansour S., Holder S.E., Brain C.E., Burton B.K., Kim K.H., Pauli R.M.,
RA   Aftimos S., Stewart H., Kim C.A., Holder-Espinasse M., Robertson S.P.,
RA   Drake W.M., Trembath R.C.;
RT   "Mutations in NOTCH2 cause Hajdu-Cheney syndrome, a disorder of severe and
RT   progressive bone loss.";
RL   Nat. Genet. 43:303-305(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1778, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   FUNCTION, INTERACTION WITH TCIM, AND SUBCELLULAR LOCATION.
RX   PubMed=25985737; DOI=10.1038/ncomms8122;
RA   Zhu P., Wang Y., Du Y., He L., Huang G., Zhang G., Yan X., Fan Z.;
RT   "C8orf4 negatively regulates self-renewal of liver cancer stem cells via
RT   suppression of NOTCH2 signalling.";
RL   Nat. Commun. 6:7122-7122(2015).
RN   [22]
RP   FUNCTION, PHOSPHORYLATION BY GSK3, UBIQUITINATION, INTERACTION WITH CUL1;
RP   SKP1; RBX1 AND FBW7, MUTAGENESIS OF THR-2416, AND CHARACTERIZATION OF
RP   VARIANT HJCYS 2317-GLN--ALA-2471 DEL.
RX   PubMed=29149593; DOI=10.1016/j.molcel.2017.10.018;
RA   Fukushima H., Shimizu K., Watahiki A., Hoshikawa S., Kosho T., Oba D.,
RA   Sakano S., Arakaki M., Yamada A., Nagashima K., Okabe K., Fukumoto S.,
RA   Jimi E., Bigas A., Nakayama K.I., Nakayama K., Aoki Y., Wei W., Inuzuka H.;
RT   "NOTCH2 Hajdu-Cheney mutations escape SCFFBW7-dependent proteolysis to
RT   promote osteoporosis.";
RL   Mol. Cell 68:645-658(2017).
RN   [23]
RP   INTERACTION WITH NOTCH2NLA; NOTCH2NLB AND NOTCH2NLC.
RX   PubMed=29856954; DOI=10.1016/j.cell.2018.03.051;
RA   Fiddes I.T., Lodewijk G.A., Mooring M., Bosworth C.M., Ewing A.D.,
RA   Mantalas G.L., Novak A.M., van den Bout A., Bishara A., Rosenkrantz J.L.,
RA   Lorig-Roach R., Field A.R., Haeussler M., Russo L., Bhaduri A.,
RA   Nowakowski T.J., Pollen A.A., Dougherty M.L., Nuttle X., Addor M.C.,
RA   Zwolinski S., Katzman S., Kriegstein A., Eichler E.E., Salama S.R.,
RA   Jacobs F.M.J., Haussler D.;
RT   "Human-specific NOTCH2NL genes affect Notch signaling and cortical
RT   neurogenesis.";
RL   Cell 173:1356-1369(2018).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MINAR1.
RX   PubMed=29329397; DOI=10.1093/jmcb/mjy002;
RA   Ho R.X., Meyer R.D., Chandler K.B., Ersoy E., Park M., Bondzie P.A.,
RA   Rahimi N., Xu H., Costello C.E., Rahimi N.;
RT   "MINAR1 is a Notch2-binding protein that inhibits angiogenesis and breast
RT   cancer growth.";
RL   J. Mol. Cell Biol. 10:195-204(2018).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1426-1677, AND DISULFIDE BONDS.
RX   PubMed=17401372; DOI=10.1038/nsmb1227;
RA   Gordon W.R., Vardar-Ulu D., Histen G., Sanchez-Irizarry C., Aster J.C.,
RA   Blacklow S.C.;
RT   "Structural basis for autoinhibition of Notch.";
RL   Nat. Struct. Mol. Biol. 14:295-300(2007).
RN   [26]
RP   VARIANT ALGS2 TYR-444.
RX   PubMed=16773578; DOI=10.1086/505332;
RA   McDaniell R., Warthen D.M., Sanchez-Lara P.A., Pai A., Krantz I.D.,
RA   Piccoli D.A., Spinner N.B.;
RT   "NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the
RT   notch signaling pathway.";
RL   Am. J. Hum. Genet. 79:169-173(2006).
RN   [27]
RP   VARIANT HJCYS 2400-ARG--ALA-2471 DEL.
RX   PubMed=21793104; DOI=10.1002/humu.21563;
RA   Isidor B., Le Merrer M., Exner G.U., Pichon O., Thierry G.,
RA   Guiochon-Mantel A., David A., Cormier-Daire V., Le Caignec C.;
RT   "Serpentine fibula-polycystic kidney syndrome caused by truncating
RT   mutations in NOTCH2.";
RL   Hum. Mutat. 32:1239-1242(2011).
RN   [28]
RP   VARIANTS HJCYS 2299-GLU--ALA-2471 DEL AND 2389-GLN--ALA-2471 DEL.
RX   PubMed=21712856; DOI=10.1038/ejhg.2011.125;
RA   Gray M.J., Kim C.A., Bertola D.R., Arantes P.R., Stewart H., Simpson M.A.,
RA   Irving M.D., Robertson S.P.;
RT   "Serpentine fibula polycystic kidney syndrome is part of the phenotypic
RT   spectrum of Hajdu-Cheney syndrome.";
RL   Eur. J. Hum. Genet. 20:122-124(2012).
RN   [29]
RP   VARIANTS HJCYS 2196-GLN--ALA-2471 DEL AND 2400-ARG--ALA-2471 DEL.
RX   PubMed=23389697; DOI=10.1007/s00198-013-2298-5;
RA   Zhao W., Petit E., Gafni R.I., Collins M.T., Robey P.G., Seton M.,
RA   Miller K.K., Mannstadt M.;
RT   "Mutations in NOTCH2 in patients with Hajdu-Cheney syndrome.";
RL   Osteoporos. Int. 24:2275-2281(2013).
CC   -!- FUNCTION: Functions as a receptor for membrane-bound ligands Jagged-1
CC       (JAG1), Jagged-2 (JAG2) and Delta-1 (DLL1) to regulate cell-fate
CC       determination. Upon ligand activation through the released notch
CC       intracellular domain (NICD) it forms a transcriptional activator
CC       complex with RBPJ/RBPSUH and activates genes of the enhancer of split
CC       locus (PubMed:21378985, PubMed:21378989). Affects the implementation of
CC       differentiation, proliferation and apoptotic programs (By similarity).
CC       Involved in bone remodeling and homeostasis. In collaboration with
CC       RELA/p65 enhances NFATc1 promoter activity and positively regulates
CC       RANKL-induced osteoclast differentiation (PubMed:29149593). Positively
CC       regulates self-renewal of liver cancer cells (PubMed:25985737).
CC       {ECO:0000250|UniProtKB:O35516, ECO:0000269|PubMed:21378985,
CC       ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:25985737,
CC       ECO:0000269|PubMed:29149593}.
CC   -!- SUBUNIT: Heterodimer of a C-terminal fragment N(TM) and an N-terminal
CC       fragment N(EC) which are probably linked by disulfide bonds (By
CC       similarity). Interacts with MAML1, MAML2 and MAML3 which act as
CC       transcriptional coactivators for NOTCH2. Interacts with RELA/p65 (By
CC       similarity). Interacts with HIF1AN. Interacts (via ANK repeats) with
CC       TCIM, the interaction inhibits the nuclear translocation of NOTCH2
CC       N2ICD (PubMed:25985737). Interacts with CUL1, RBX1, SKP1 and FBXW7 that
CC       are SCF(FBXW7) E3 ubiquitin-protein ligase complex components
CC       (PubMed:29149593). Interacts with MINAR1; this interaction increases
CC       MINAR1 stability and function (PubMed:29329397). Interacts with
CC       NOTCH2NL (NOTCH2NLA, NOTCH2NLB and/or NOTCH2NLC); leading to enhance
CC       Notch signaling pathway in a non-cell-autonomous manner
CC       (PubMed:29856954). Interacts with MDK; this interaction mediates a
CC       nuclear accumulation of NOTCH2 and therefore activation of NOTCH2
CC       signaling leading to interaction between HES1 and STAT3
CC       (PubMed:18469519). {ECO:0000250, ECO:0000269|PubMed:11101851,
CC       ECO:0000269|PubMed:12370315, ECO:0000269|PubMed:17573339,
CC       ECO:0000269|PubMed:18469519, ECO:0000269|PubMed:25985737,
CC       ECO:0000269|PubMed:29149593, ECO:0000269|PubMed:29329397,
CC       ECO:0000269|PubMed:29856954}.
CC   -!- SUBCELLULAR LOCATION: [Notch 2 extracellular truncation]: Cell membrane
CC       {ECO:0000269|PubMed:29329397, ECO:0000269|PubMed:9244302}; Single-pass
CC       type I membrane protein {ECO:0000269|PubMed:9244302}.
CC   -!- SUBCELLULAR LOCATION: [Notch 2 intracellular domain]: Nucleus
CC       {ECO:0000269|PubMed:25985737}. Cytoplasm {ECO:0000269|PubMed:25985737}.
CC       Note=Following proteolytical processing NICD is translocated to the
CC       nucleus. Retained at the cytoplasm by TCIM (PubMed:25985737).
CC       {ECO:0000269|PubMed:25985737}.
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, heart, kidney, lung,
CC       skeletal muscle and liver. Ubiquitously expressed in the embryo.
CC       {ECO:0000269|PubMed:21378985}.
CC   -!- PTM: Synthesized in the endoplasmic reticulum as an inactive form which
CC       is proteolytically cleaved by a furin-like convertase in the trans-
CC       Golgi network before it reaches the plasma membrane to yield an active,
CC       ligand-accessible form (By similarity). Cleavage results in a C-
CC       terminal fragment N(TM) and a N-terminal fragment N(EC) (By
CC       similarity). Following ligand binding, it is cleaved by TNF-alpha
CC       converting enzyme (TACE) to yield a membrane-associated intermediate
CC       fragment called notch extracellular truncation (NEXT) (By similarity).
CC       This fragment is then cleaved by presenilin dependent gamma-secretase
CC       to release a notch-derived peptide containing the intracellular domain
CC       (NICD) from the membrane (By similarity).
CC       {ECO:0000250|UniProtKB:O35516, ECO:0000250|UniProtKB:Q01705}.
CC   -!- PTM: Hydroxylated by HIF1AN. {ECO:0000269|PubMed:18299578}.
CC   -!- PTM: Can be either O-glucosylated or O-xylosylated at Ser-613 by
CC       POGLUT1. {ECO:0000250|UniProtKB:O35516}.
CC   -!- PTM: Phosphorylated by GSK3. GSK3-mediated phosphorylation is necessary
CC       for NOTCH2 recognition by FBXW7, ubiquitination and degradation via the
CC       ubiquitin proteasome pathway. {ECO:0000269|PubMed:29149593}.
CC   -!- DISEASE: Alagille syndrome 2 (ALGS2) [MIM:610205]: A form of Alagille
CC       syndrome, an autosomal dominant multisystem disorder. It is clinically
CC       defined by hepatic bile duct paucity and cholestasis in association
CC       with cardiac, skeletal, and ophthalmologic manifestations. There are
CC       characteristic facial features and less frequent clinical involvement
CC       of the renal and vascular systems. {ECO:0000269|PubMed:16773578}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Hajdu-Cheney syndrome (HJCYS) [MIM:102500]: A rare, autosomal
CC       dominant skeletal disorder characterized by the association of facial
CC       anomalies, acro-osteolysis, general osteoporosis, insufficient
CC       ossification of the skull, and periodontal disease (premature loss of
CC       permanent teeth). Other features include cleft palate, congenital heart
CC       defects, polycystic kidneys, orthopedic problems and anomalies of the
CC       genitalia, intestines and eyes. {ECO:0000269|PubMed:21378985,
CC       ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:21681853,
CC       ECO:0000269|PubMed:21712856, ECO:0000269|PubMed:21793104,
CC       ECO:0000269|PubMed:23389697, ECO:0000269|PubMed:29149593}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry. NOTCH2 nonsense and frameshift mutations associated with Hajdu-
CC       Cheney syndrome cluster to the last coding exon of the gene. Mutant
CC       mRNA products escape nonsense-mediated decay and the resulting
CC       truncated NOTCH2 proteins act in a gain-of-function manner
CC       (PubMed:21378989). The pathological mechanism at cellular level
CC       involves disruption of a high affinity degron recognized by FBXW7 at
CC       the C-terminus, loss of interaction with FBXW7, reduced ubiquitination
CC       and degradation, and increased NOTCH2 levels. Bone marrow cells derived
CC       from HJCYS patients have an enhanced capacity of osteoclastogenesis due
CC       to sustained NOTCH2 activity (PubMed:29149593).
CC       {ECO:0000269|PubMed:21378989, ECO:0000269|PubMed:29149593}.
CC   -!- SIMILARITY: Belongs to the NOTCH family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NOTCH2ID41556ch1p12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF308601; AAA36377.2; -; mRNA.
DR   EMBL; AF315356; AAG37073.1; -; mRNA.
DR   EMBL; AL359752; CAI18974.1; -; Genomic_DNA.
DR   EMBL; AL512503; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAI18974.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH72483.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH72483.1; JOINED; Genomic_DNA.
DR   EMBL; AL596222; CAH70182.1; -; Genomic_DNA.
DR   EMBL; AL359752; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; AL512503; CAH70182.1; JOINED; Genomic_DNA.
DR   EMBL; U77493; AAB19224.1; -; mRNA.
DR   CCDS; CCDS908.1; -.
DR   RefSeq; NP_001186930.1; NM_001200001.1.
DR   RefSeq; NP_077719.2; NM_024408.3.
DR   PDB; 2OO4; X-ray; 2.00 A; A/B=1423-1677.
DR   PDB; 5MWB; X-ray; 1.86 A; A=414-532.
DR   PDBsum; 2OO4; -.
DR   PDBsum; 5MWB; -.
DR   AlphaFoldDB; Q04721; -.
DR   SMR; Q04721; -.
DR   BioGRID; 110915; 447.
DR   CORUM; Q04721; -.
DR   ELM; Q04721; -.
DR   IntAct; Q04721; 69.
DR   MINT; Q04721; -.
DR   STRING; 9606.ENSP00000256646; -.
DR   BindingDB; Q04721; -.
DR   ChEMBL; CHEMBL3407320; -.
DR   GuidetoPHARMACOLOGY; 2859; -.
DR   GlyConnect; 1553; 2 N-Linked glycans (1 site).
DR   GlyGen; Q04721; 11 sites, 2 N-linked glycans (1 site), 1 O-linked glycan (3 sites), 1 Ser glycan (1 site), 1 Thr glycan (1 site).
DR   iPTMnet; Q04721; -.
DR   PhosphoSitePlus; Q04721; -.
DR   BioMuta; NOTCH2; -.
DR   DMDM; 143811429; -.
DR   EPD; Q04721; -.
DR   jPOST; Q04721; -.
DR   MassIVE; Q04721; -.
DR   MaxQB; Q04721; -.
DR   PaxDb; Q04721; -.
DR   PeptideAtlas; Q04721; -.
DR   PRIDE; Q04721; -.
DR   ProteomicsDB; 58265; -.
DR   ABCD; Q04721; 25 sequenced antibodies.
DR   Antibodypedia; 20208; 678 antibodies from 42 providers.
DR   DNASU; 4853; -.
DR   Ensembl; ENST00000256646.7; ENSP00000256646.2; ENSG00000134250.21.
DR   GeneID; 4853; -.
DR   KEGG; hsa:4853; -.
DR   MANE-Select; ENST00000256646.7; ENSP00000256646.2; NM_024408.4; NP_077719.2.
DR   UCSC; uc001eik.4; human.
DR   CTD; 4853; -.
DR   DisGeNET; 4853; -.
DR   GeneCards; NOTCH2; -.
DR   GeneReviews; NOTCH2; -.
DR   HGNC; HGNC:7882; NOTCH2.
DR   HPA; ENSG00000134250; Low tissue specificity.
DR   MalaCards; NOTCH2; -.
DR   MIM; 102500; phenotype.
DR   MIM; 600275; gene.
DR   MIM; 610205; phenotype.
DR   neXtProt; NX_Q04721; -.
DR   OpenTargets; ENSG00000134250; -.
DR   Orphanet; 261629; Alagille syndrome due to a NOTCH2 point mutation.
DR   Orphanet; 955; Hajdu-Cheney syndrome.
DR   PharmGKB; PA31684; -.
DR   VEuPathDB; HostDB:ENSG00000134250; -.
DR   eggNOG; KOG1217; Eukaryota.
DR   GeneTree; ENSGT00940000155030; -.
DR   HOGENOM; CLU_000576_0_0_1; -.
DR   InParanoid; Q04721; -.
DR   OMA; PGYEGNH; -.
DR   OrthoDB; 7525at2759; -.
DR   PhylomeDB; Q04721; -.
DR   TreeFam; TF351641; -.
DR   PathwayCommons; Q04721; -.
DR   Reactome; R-HSA-1912399; Pre-NOTCH Processing in the Endoplasmic Reticulum.
DR   Reactome; R-HSA-1912408; Pre-NOTCH Transcription and Translation.
DR   Reactome; R-HSA-1912420; Pre-NOTCH Processing in Golgi.
DR   Reactome; R-HSA-2197563; NOTCH2 intracellular domain regulates transcription.
DR   Reactome; R-HSA-2979096; NOTCH2 Activation and Transmission of Signal to the Nucleus.
DR   Reactome; R-HSA-350054; Notch-HLH transcription pathway.
DR   Reactome; R-HSA-5083630; Defective LFNG causes SCDO3.
DR   Reactome; R-HSA-9013695; NOTCH4 Intracellular Domain Regulates Transcription.
DR   SignaLink; Q04721; -.
DR   SIGNOR; Q04721; -.
DR   BioGRID-ORCS; 4853; 13 hits in 1075 CRISPR screens.
DR   ChiTaRS; NOTCH2; human.
DR   EvolutionaryTrace; Q04721; -.
DR   GeneWiki; Notch-2; -.
DR   GenomeRNAi; 4853; -.
DR   Pharos; Q04721; Tchem.
DR   PRO; PR:Q04721; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q04721; protein.
DR   Bgee; ENSG00000134250; Expressed in pigmented layer of retina and 203 other tissues.
DR   ExpressionAtlas; Q04721; baseline and differential.
DR   Genevisible; Q04721; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; IEA:Ensembl.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0051059; F:NF-kappaB binding; IEA:Ensembl.
DR   GO; GO:0038023; F:signaling receptor activity; NAS:UniProtKB.
DR   GO; GO:0009887; P:animal organ morphogenesis; IEP:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0060413; P:atrial septum morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0003162; P:atrioventricular node development; NAS:BHF-UCL.
DR   GO; GO:0007411; P:axon guidance; IBA:GO_Central.
DR   GO; GO:0030509; P:BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0046849; P:bone remodeling; IMP:UniProtKB.
DR   GO; GO:0001709; P:cell fate determination; TAS:UniProtKB.
DR   GO; GO:0071228; P:cellular response to tumor cell; IDA:UniProtKB.
DR   GO; GO:1990705; P:cholangiocyte proliferation; IEA:Ensembl.
DR   GO; GO:0061073; P:ciliary body morphogenesis; IEA:Ensembl.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; IEA:Ensembl.
DR   GO; GO:0072104; P:glomerular capillary formation; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; IEA:Ensembl.
DR   GO; GO:0030097; P:hemopoiesis; TAS:UniProtKB.
DR   GO; GO:0072574; P:hepatocyte proliferation; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0035622; P:intrahepatic bile duct development; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0002315; P:marginal zone B cell differentiation; ISS:UniProtKB.
DR   GO; GO:0002011; P:morphogenesis of an epithelial sheet; IEA:Ensembl.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0043011; P:myeloid dendritic cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; NAS:UniProtKB.
DR   GO; GO:0061314; P:Notch signaling involved in heart development; IC:BHF-UCL.
DR   GO; GO:0007219; P:Notch signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060674; P:placenta blood vessel development; IEA:Ensembl.
DR   GO; GO:0072015; P:podocyte development; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010838; P:positive regulation of keratinocyte proliferation; IDA:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IEA:Ensembl.
DR   GO; GO:0046579; P:positive regulation of Ras protein signal transduction; IDA:UniProtKB.
DR   GO; GO:0072014; P:proximal tubule development; IEA:Ensembl.
DR   GO; GO:0003184; P:pulmonary valve morphogenesis; IMP:BHF-UCL.
DR   GO; GO:2000249; P:regulation of actin cytoskeleton reorganization; IDA:UniProtKB.
DR   GO; GO:2001204; P:regulation of osteoclast development; IMP:UniProtKB.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   Gene3D; 1.25.40.20; -; 1.
DR   IDEAL; IID00463; -.
DR   InterPro; IPR002110; Ankyrin_rpt.
DR   InterPro; IPR036770; Ankyrin_rpt-contain_sf.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR013032; EGF-like_CS.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR008297; Notch.
DR   InterPro; IPR035993; Notch-like_dom_sf.
DR   InterPro; IPR022336; Notch_2.
DR   InterPro; IPR024600; Notch_C.
DR   InterPro; IPR000800; Notch_dom.
DR   InterPro; IPR010660; Notch_NOD_dom.
DR   InterPro; IPR011656; Notch_NODP_dom.
DR   Pfam; PF12796; Ank_2; 1.
DR   Pfam; PF13857; Ank_5; 1.
DR   Pfam; PF00008; EGF; 24.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF12661; hEGF; 3.
DR   Pfam; PF06816; NOD; 1.
DR   Pfam; PF07684; NODP; 1.
DR   Pfam; PF00066; Notch; 3.
DR   PIRSF; PIRSF002279; Notch; 1.
DR   PRINTS; PR01452; LNOTCHREPEAT.
DR   PRINTS; PR01985; NOTCH2.
DR   SMART; SM00248; ANK; 6.
DR   SMART; SM01334; DUF3454; 1.
DR   SMART; SM00181; EGF; 36.
DR   SMART; SM00179; EGF_CA; 34.
DR   SMART; SM00004; NL; 3.
DR   SMART; SM01338; NOD; 1.
DR   SMART; SM01339; NODP; 1.
DR   SUPFAM; SSF48403; SSF48403; 1.
DR   SUPFAM; SSF57184; SSF57184; 6.
DR   SUPFAM; SSF90193; SSF90193; 2.
DR   PROSITE; PS50297; ANK_REP_REGION; 1.
DR   PROSITE; PS50088; ANK_REPEAT; 4.
DR   PROSITE; PS00010; ASX_HYDROXYL; 22.
DR   PROSITE; PS00022; EGF_1; 34.
DR   PROSITE; PS01186; EGF_2; 29.
DR   PROSITE; PS50026; EGF_3; 35.
DR   PROSITE; PS01187; EGF_CA; 22.
DR   PROSITE; PS50258; LNR; 3.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; ANK repeat; Cell membrane; Cytoplasm;
KW   Developmental protein; Differentiation; Disease variant; Disulfide bond;
KW   EGF-like domain; Glycoprotein; Membrane; Notch signaling pathway; Nucleus;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Signal;
KW   Transcription; Transcription regulation; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..2471
FT                   /note="Neurogenic locus notch homolog protein 2"
FT                   /id="PRO_0000007683"
FT   CHAIN           1666..2471
FT                   /note="Notch 2 extracellular truncation"
FT                   /evidence="ECO:0000250|UniProtKB:Q01705"
FT                   /id="PRO_0000007684"
FT   CHAIN           1697..2471
FT                   /note="Notch 2 intracellular domain"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT                   /id="PRO_0000007685"
FT   TOPO_DOM        26..1677
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1678..1698
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1699..2471
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..63
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          64..102
FT                   /note="EGF-like 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          105..143
FT                   /note="EGF-like 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          144..180
FT                   /note="EGF-like 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          182..219
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          221..258
FT                   /note="EGF-like 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          260..296
FT                   /note="EGF-like 7; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          298..336
FT                   /note="EGF-like 8; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          338..374
FT                   /note="EGF-like 9; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          375..413
FT                   /note="EGF-like 10"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          415..454
FT                   /note="EGF-like 11; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          456..492
FT                   /note="EGF-like 12; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          494..530
FT                   /note="EGF-like 13; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          532..568
FT                   /note="EGF-like 14; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          570..605
FT                   /note="EGF-like 15; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          607..643
FT                   /note="EGF-like 16; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          645..680
FT                   /note="EGF-like 17; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          682..718
FT                   /note="EGF-like 18; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          720..755
FT                   /note="EGF-like 19"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          757..793
FT                   /note="EGF-like 20; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          795..831
FT                   /note="EGF-like 21; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          833..871
FT                   /note="EGF-like 22"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          873..909
FT                   /note="EGF-like 23; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          911..947
FT                   /note="EGF-like 24; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          949..985
FT                   /note="EGF-like 25; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          987..1023
FT                   /note="EGF-like 26; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1025..1061
FT                   /note="EGF-like 27; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1063..1099
FT                   /note="EGF-like 28"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1101..1147
FT                   /note="EGF-like 29"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          1149..1185
FT                   /note="EGF-like 30; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1187..1223
FT                   /note="EGF-like 31; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1225..1262
FT                   /note="EGF-like 32; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1264..1302
FT                   /note="EGF-like 33"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1304..1343
FT                   /note="EGF-like 34"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          1374..1412
FT                   /note="EGF-like 35"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   REPEAT          1425..1465
FT                   /note="LNR 1"
FT   REPEAT          1466..1502
FT                   /note="LNR 2"
FT   REPEAT          1503..1544
FT                   /note="LNR 3"
FT   REPEAT          1827..1871
FT                   /note="ANK 1"
FT   REPEAT          1876..1905
FT                   /note="ANK 2"
FT   REPEAT          1909..1939
FT                   /note="ANK 3"
FT   REPEAT          1943..1972
FT                   /note="ANK 4"
FT   REPEAT          1976..2005
FT                   /note="ANK 5"
FT   REPEAT          2009..2038
FT                   /note="ANK 6"
FT   REGION          1425..1677
FT                   /note="Negative regulatory region (NRR)"
FT   REGION          1754..1788
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2091..2168
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2380..2471
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1760..1788
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2123..2138
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2139..2168
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2384..2403
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        2419..2447
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            614
FT                   /note="Essential for O-xylosylation"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   MOD_RES         1716
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1778
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1802
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1804
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1808
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1842
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   MOD_RES         1845
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         2070
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2078
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QW30"
FT   MOD_RES         2081
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         2097
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   CARBOHYD        46
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        155
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        613
FT                   /note="O-linked (Glc...) serine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   CARBOHYD        613
FT                   /note="O-linked (Xyl...) serine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:O35516"
FT   CARBOHYD        733
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1102
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1465
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        28..41
FT                   /evidence="ECO:0000250"
FT   DISULFID        35..51
FT                   /evidence="ECO:0000250"
FT   DISULFID        53..62
FT                   /evidence="ECO:0000250"
FT   DISULFID        68..79
FT                   /evidence="ECO:0000250"
FT   DISULFID        73..90
FT                   /evidence="ECO:0000250"
FT   DISULFID        92..101
FT                   /evidence="ECO:0000250"
FT   DISULFID        109..121
FT                   /evidence="ECO:0000250"
FT   DISULFID        115..131
FT                   /evidence="ECO:0000250"
FT   DISULFID        133..142
FT                   /evidence="ECO:0000250"
FT   DISULFID        148..159
FT                   /evidence="ECO:0000250"
FT   DISULFID        153..168
FT                   /evidence="ECO:0000250"
FT   DISULFID        170..179
FT                   /evidence="ECO:0000250"
FT   DISULFID        186..198
FT                   /evidence="ECO:0000250"
FT   DISULFID        192..207
FT                   /evidence="ECO:0000250"
FT   DISULFID        209..218
FT                   /evidence="ECO:0000250"
FT   DISULFID        225..236
FT                   /evidence="ECO:0000250"
FT   DISULFID        230..246
FT                   /evidence="ECO:0000250"
FT   DISULFID        248..257
FT                   /evidence="ECO:0000250"
FT   DISULFID        264..275
FT                   /evidence="ECO:0000250"
FT   DISULFID        269..284
FT                   /evidence="ECO:0000250"
FT   DISULFID        286..295
FT                   /evidence="ECO:0000250"
FT   DISULFID        302..315
FT                   /evidence="ECO:0000250"
FT   DISULFID        309..324
FT                   /evidence="ECO:0000250"
FT   DISULFID        326..335
FT                   /evidence="ECO:0000250"
FT   DISULFID        342..353
FT                   /evidence="ECO:0000250"
FT   DISULFID        347..362
FT                   /evidence="ECO:0000250"
FT   DISULFID        364..373
FT                   /evidence="ECO:0000250"
FT   DISULFID        379..390
FT                   /evidence="ECO:0000250"
FT   DISULFID        384..401
FT                   /evidence="ECO:0000250"
FT   DISULFID        403..412
FT                   /evidence="ECO:0000250"
FT   DISULFID        419..433
FT                   /evidence="ECO:0000250"
FT   DISULFID        427..442
FT                   /evidence="ECO:0000250"
FT   DISULFID        444..453
FT                   /evidence="ECO:0000250"
FT   DISULFID        460..471
FT                   /evidence="ECO:0000250"
FT   DISULFID        465..480
FT                   /evidence="ECO:0000250"
FT   DISULFID        482..491
FT                   /evidence="ECO:0000250"
FT   DISULFID        498..509
FT                   /evidence="ECO:0000250"
FT   DISULFID        503..518
FT                   /evidence="ECO:0000250"
FT   DISULFID        520..529
FT                   /evidence="ECO:0000250"
FT   DISULFID        536..547
FT                   /evidence="ECO:0000250"
FT   DISULFID        541..556
FT                   /evidence="ECO:0000250"
FT   DISULFID        558..567
FT                   /evidence="ECO:0000250"
FT   DISULFID        574..584
FT                   /evidence="ECO:0000250"
FT   DISULFID        579..593
FT                   /evidence="ECO:0000250"
FT   DISULFID        595..604
FT                   /evidence="ECO:0000250"
FT   DISULFID        611..622
FT                   /evidence="ECO:0000250"
FT   DISULFID        616..631
FT                   /evidence="ECO:0000250"
FT   DISULFID        633..642
FT                   /evidence="ECO:0000250"
FT   DISULFID        649..659
FT                   /evidence="ECO:0000250"
FT   DISULFID        654..668
FT                   /evidence="ECO:0000250"
FT   DISULFID        670..679
FT                   /evidence="ECO:0000250"
FT   DISULFID        686..697
FT                   /evidence="ECO:0000250"
FT   DISULFID        691..706
FT                   /evidence="ECO:0000250"
FT   DISULFID        708..717
FT                   /evidence="ECO:0000250"
FT   DISULFID        724..734
FT                   /evidence="ECO:0000250"
FT   DISULFID        729..743
FT                   /evidence="ECO:0000250"
FT   DISULFID        745..754
FT                   /evidence="ECO:0000250"
FT   DISULFID        761..772
FT                   /evidence="ECO:0000250"
FT   DISULFID        766..781
FT                   /evidence="ECO:0000250"
FT   DISULFID        783..792
FT                   /evidence="ECO:0000250"
FT   DISULFID        799..810
FT                   /evidence="ECO:0000250"
FT   DISULFID        804..819
FT                   /evidence="ECO:0000250"
FT   DISULFID        821..830
FT                   /evidence="ECO:0000250"
FT   DISULFID        837..848
FT                   /evidence="ECO:0000250"
FT   DISULFID        842..859
FT                   /evidence="ECO:0000250"
FT   DISULFID        861..870
FT                   /evidence="ECO:0000250"
FT   DISULFID        877..888
FT                   /evidence="ECO:0000250"
FT   DISULFID        882..897
FT                   /evidence="ECO:0000250"
FT   DISULFID        899..908
FT                   /evidence="ECO:0000250"
FT   DISULFID        915..926
FT                   /evidence="ECO:0000250"
FT   DISULFID        920..935
FT                   /evidence="ECO:0000250"
FT   DISULFID        937..946
FT                   /evidence="ECO:0000250"
FT   DISULFID        953..964
FT                   /evidence="ECO:0000250"
FT   DISULFID        958..973
FT                   /evidence="ECO:0000250"
FT   DISULFID        975..984
FT                   /evidence="ECO:0000250"
FT   DISULFID        991..1002
FT                   /evidence="ECO:0000250"
FT   DISULFID        996..1011
FT                   /evidence="ECO:0000250"
FT   DISULFID        1013..1022
FT                   /evidence="ECO:0000250"
FT   DISULFID        1029..1040
FT                   /evidence="ECO:0000250"
FT   DISULFID        1034..1049
FT                   /evidence="ECO:0000250"
FT   DISULFID        1051..1060
FT                   /evidence="ECO:0000250"
FT   DISULFID        1067..1078
FT                   /evidence="ECO:0000250"
FT   DISULFID        1072..1087
FT                   /evidence="ECO:0000250"
FT   DISULFID        1089..1098
FT                   /evidence="ECO:0000250"
FT   DISULFID        1105..1126
FT                   /evidence="ECO:0000305"
FT   DISULFID        1120..1135
FT                   /evidence="ECO:0000250"
FT   DISULFID        1137..1146
FT                   /evidence="ECO:0000250"
FT   DISULFID        1153..1164
FT                   /evidence="ECO:0000250"
FT   DISULFID        1158..1173
FT                   /evidence="ECO:0000250"
FT   DISULFID        1175..1184
FT                   /evidence="ECO:0000250"
FT   DISULFID        1191..1202
FT                   /evidence="ECO:0000250"
FT   DISULFID        1196..1211
FT                   /evidence="ECO:0000250"
FT   DISULFID        1213..1222
FT                   /evidence="ECO:0000250"
FT   DISULFID        1229..1241
FT                   /evidence="ECO:0000250"
FT   DISULFID        1235..1250
FT                   /evidence="ECO:0000250"
FT   DISULFID        1252..1261
FT                   /evidence="ECO:0000250"
FT   DISULFID        1268..1281
FT                   /evidence="ECO:0000250"
FT   DISULFID        1273..1290
FT                   /evidence="ECO:0000250"
FT   DISULFID        1292..1301
FT                   /evidence="ECO:0000250"
FT   DISULFID        1308..1319
FT                   /evidence="ECO:0000250"
FT   DISULFID        1313..1331
FT                   /evidence="ECO:0000250"
FT   DISULFID        1333..1342
FT                   /evidence="ECO:0000250"
FT   DISULFID        1378..1389
FT                   /evidence="ECO:0000250"
FT   DISULFID        1383..1400
FT                   /evidence="ECO:0000250"
FT   DISULFID        1402..1411
FT                   /evidence="ECO:0000250"
FT   DISULFID        1425..1448
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1430..1443
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1439..1455
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1466..1489
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1472..1484
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1480..1496
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1503..1527
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1509..1522
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1518..1534
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   DISULFID        1632..1639
FT                   /evidence="ECO:0000269|PubMed:17401372"
FT   VARIANT         444
FT                   /note="C -> Y (in ALGS2; dbSNP:rs111033632)"
FT                   /evidence="ECO:0000269|PubMed:16773578"
FT                   /id="VAR_029361"
FT   VARIANT         1667
FT                   /note="V -> F (in dbSNP:rs17024517)"
FT                   /id="VAR_031463"
FT   VARIANT         2140..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985"
FT                   /id="VAR_080195"
FT   VARIANT         2196..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:23389697"
FT                   /id="VAR_080196"
FT   VARIANT         2208..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985,
FT                   ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080197"
FT   VARIANT         2223..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080198"
FT   VARIANT         2285..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378989"
FT                   /id="VAR_080199"
FT   VARIANT         2299..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21712856"
FT                   /id="VAR_080200"
FT   VARIANT         2317..2471
FT                   /note="Missing (in HJCYS; loss of interaction with FBW7;
FT                   decreased ubiquitination)"
FT                   /evidence="ECO:0000269|PubMed:21378989,
FT                   ECO:0000269|PubMed:29149593"
FT                   /id="VAR_080201"
FT   VARIANT         2325..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985"
FT                   /id="VAR_080202"
FT   VARIANT         2360..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21681853"
FT                   /id="VAR_080203"
FT   VARIANT         2373..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378989"
FT                   /id="VAR_080204"
FT   VARIANT         2389..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21712856"
FT                   /id="VAR_080205"
FT   VARIANT         2400..2471
FT                   /note="Missing (in HJCYS)"
FT                   /evidence="ECO:0000269|PubMed:21378985,
FT                   ECO:0000269|PubMed:21793104, ECO:0000269|PubMed:23389697"
FT                   /id="VAR_080206"
FT   MUTAGEN         2416
FT                   /note="T->A: Loss of interaction with FBW7. Results in
FT                   decreased ubiquitination and degradation."
FT                   /evidence="ECO:0000269|PubMed:29149593"
FT   CONFLICT        21
FT                   /note="A -> T (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        210
FT                   /note="P -> L (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1037
FT                   /note="E -> D (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1084..1085
FT                   /note="ES -> SP (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1094
FT                   /note="A -> V (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1139
FT                   /note="L -> V (in Ref. 4; AAB19224)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1519
FT                   /note="D -> N (in Ref. 1; AAA36377)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2053
FT                   /note="R -> H (in Ref. 2; AAG37073)"
FT                   /evidence="ECO:0000305"
FT   TURN            418..420
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          426..428
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          432..436
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          439..443
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          448..450
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   HELIX           459..462
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          470..474
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          477..481
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          486..488
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   HELIX           497..500
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          508..512
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   STRAND          515..519
FT                   /evidence="ECO:0007829|PDB:5MWB"
FT   HELIX           1428..1433
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1436..1438
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1441..1443
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   TURN            1446..1448
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1449..1452
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   TURN            1453..1458
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   TURN            1462..1465
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1472..1474
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1477..1479
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1482..1484
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   TURN            1487..1490
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1491..1494
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1506..1512
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1515..1517
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1520..1522
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1525..1532
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1544..1553
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1555..1560
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1562..1573
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1575..1579
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1589..1595
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1618..1628
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1632..1635
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   HELIX           1643..1656
FT                   /evidence="ECO:0007829|PDB:2OO4"
FT   STRAND          1663..1670
FT                   /evidence="ECO:0007829|PDB:2OO4"
SQ   SEQUENCE   2471 AA;  265405 MW;  605B1B963C812BE1 CRC64;
     MPALRPALLW ALLALWLCCA APAHALQCRD GYEPCVNEGM CVTYHNGTGY CKCPEGFLGE
     YCQHRDPCEK NRCQNGGTCV AQAMLGKATC RCASGFTGED CQYSTSHPCF VSRPCLNGGT
     CHMLSRDTYE CTCQVGFTGK ECQWTDACLS HPCANGSTCT TVANQFSCKC LTGFTGQKCE
     TDVNECDIPG HCQHGGTCLN LPGSYQCQCP QGFTGQYCDS LYVPCAPSPC VNGGTCRQTG
     DFTFECNCLP GFEGSTCERN IDDCPNHRCQ NGGVCVDGVN TYNCRCPPQW TGQFCTEDVD
     ECLLQPNACQ NGGTCANRNG GYGCVCVNGW SGDDCSENID DCAFASCTPG STCIDRVASF
     SCMCPEGKAG LLCHLDDACI SNPCHKGALC DTNPLNGQYI CTCPQGYKGA DCTEDVDECA
     MANSNPCEHA GKCVNTDGAF HCECLKGYAG PRCEMDINEC HSDPCQNDAT CLDKIGGFTC
     LCMPGFKGVH CELEINECQS NPCVNNGQCV DKVNRFQCLC PPGFTGPVCQ IDIDDCSSTP
     CLNGAKCIDH PNGYECQCAT GFTGVLCEEN IDNCDPDPCH HGQCQDGIDS YTCICNPGYM
     GAICSDQIDE CYSSPCLNDG RCIDLVNGYQ CNCQPGTSGV NCEINFDDCA SNPCIHGICM
     DGINRYSCVC SPGFTGQRCN IDIDECASNP CRKGATCING VNGFRCICPE GPHHPSCYSQ
     VNECLSNPCI HGNCTGGLSG YKCLCDAGWV GINCEVDKNE CLSNPCQNGG TCDNLVNGYR
     CTCKKGFKGY NCQVNIDECA SNPCLNQGTC FDDISGYTCH CVLPYTGKNC QTVLAPCSPN
     PCENAAVCKE SPNFESYTCL CAPGWQGQRC TIDIDECISK PCMNHGLCHN TQGSYMCECP
     PGFSGMDCEE DIDDCLANPC QNGGSCMDGV NTFSCLCLPG FTGDKCQTDM NECLSEPCKN
     GGTCSDYVNS YTCKCQAGFD GVHCENNINE CTESSCFNGG TCVDGINSFS CLCPVGFTGS
     FCLHEINECS SHPCLNEGTC VDGLGTYRCS CPLGYTGKNC QTLVNLCSRS PCKNKGTCVQ
     KKAESQCLCP SGWAGAYCDV PNVSCDIAAS RRGVLVEHLC QHSGVCINAG NTHYCQCPLG
     YTGSYCEEQL DECASNPCQH GATCSDFIGG YRCECVPGYQ GVNCEYEVDE CQNQPCQNGG
     TCIDLVNHFK CSCPPGTRGL LCEENIDDCA RGPHCLNGGQ CMDRIGGYSC RCLPGFAGER
     CEGDINECLS NPCSSEGSLD CIQLTNDYLC VCRSAFTGRH CETFVDVCPQ MPCLNGGTCA
     VASNMPDGFI CRCPPGFSGA RCQSSCGQVK CRKGEQCVHT ASGPRCFCPS PRDCESGCAS
     SPCQHGGSCH PQRQPPYYSC QCAPPFSGSR CELYTAPPST PPATCLSQYC ADKARDGVCD
     EACNSHACQW DGGDCSLTME NPWANCSSPL PCWDYINNQC DELCNTVECL FDNFECQGNS
     KTCKYDKYCA DHFKDNHCDQ GCNSEECGWD GLDCAADQPE NLAEGTLVIV VLMPPEQLLQ
     DARSFLRALG TLLHTNLRIK RDSQGELMVY PYYGEKSAAM KKQRMTRRSL PGEQEQEVAG
     SKVFLEIDNR QCVQDSDHCF KNTDAAAALL ASHAIQGTLS YPLVSVVSES LTPERTQLLY
     LLAVAVVIIL FIILLGVIMA KRKRKHGSLW LPEGFTLRRD ASNHKRREPV GQDAVGLKNL
     SVQVSEANLI GTGTSEHWVD DEGPQPKKVK AEDEALLSEE DDPIDRRPWT QQHLEAADIR
     RTPSLALTPP QAEQEVDVLD VNVRGPDGCT PLMLASLRGG SSDLSDEDED AEDSSANIIT
     DLVYQGASLQ AQTDRTGEMA LHLAARYSRA DAAKRLLDAG ADANAQDNMG RCPLHAAVAA
     DAQGVFQILI RNRVTDLDAR MNDGTTPLIL AARLAVEGMV AELINCQADV NAVDDHGKSA
     LHWAAAVNNV EATLLLLKNG ANRDMQDNKE ETPLFLAARE GSYEAAKILL DHFANRDITD
     HMDRLPRDVA RDRMHHDIVR LLDEYNVTPS PPGTVLTSAL SPVICGPNRS FLSLKHTPMG
     KKSRRPSAKS TMPTSLPNLA KEAKDAKGSR RKKSLSEKVQ LSESSVTLSP VDSLESPHTY
     VSDTTSSPMI TSPGILQASP NPMLATAAPP APVHAQHALS FSNLHEMQPL AHGASTVLPS
     VSQLLSHHHI VSPGSGSAGS LSRLHPVPVP ADWMNRMEVN ETQYNEMFGM VLAPAEGTHP
     GIAPQSRPPE GKHITTPREP LPPIVTFQLI PKGSIAQPAG APQPQSTCPP AVAGPLPTMY
     QIPEMARLPS VAFPTAMMPQ QDGQVAQTIL PAYHPFPASV GKYPTPPSQH SYASSNAAER
     TPSHSGHLQG EHPYLTPSPE SPDQWSSSSP HSASDWSDVT TSPTPGGAGG GQRGPGTHMS
     EPPHNNMQVY A
//
